Open AccessP1231: ZILOVERTAMAB VEDOTIN (MK‐2140) FOR THE TREATMENT OF NON‐HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE‐001 STUDY OF AN ANTI‐ROR1 ANTIBODY‐DRUG CONJUGATE
Author(s) -
Wang M.,
Mei M.,
Barr P. M.,
Barrientos J.,
Vos S.,
Furman R.,
Patel K.,
Thompson P. A.,
Choi M.,
Kallam A.,
Zhu Y.,
Chakraborty S.,
Marinello P.,
Spurgeon S. E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847788.96420.63
Subject(s) - medicine , follicular lymphoma , lymphoma , lymphoplasmacytic lymphoma , mantle cell lymphoma , brentuximab vedotin , antibody drug conjugate , oncology , pharmacology , immunology , antibody , waldenstrom macroglobulinemia , monoclonal antibody , cd30